Chemotherapy Foundation Symposium (CFS) 35th Annual Conference
In-Person Event
Nov 08 - 10, 2017
New York, New York, USA
OVERVIEW
Chemotherapy Foundation Symposium (CFS) 35th Annual Conference is organized by Physicians Education Resource, LLC (PER) and will be held during Nov 08 - 10, 2017 at New York Marriott Marquis, New York, United States of America.
The target audience for this medical event for oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend. This CME Conference has been approved FOR a maximum of 21.75 AMA PRA Category 1 Credits.
Course Description :
Advances in all aspects of cancer care—including diagnostic, therapeutic, and supportive strategies—form the foundation for recent changes in the management of solid and hematologic malignancies. For many tumor types, integration into practice of novel testing approaches, systemic therapies, molecular targeted therapies, immunotherapies, and multimodal strategies, continue to improve patient outcomes in multiple lines of care. Each year, the CFS®, brings together more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers, with the aim of promoting the delivery of state-of-the-art cancer care for the most challenging clinical scenarios. At the 34th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics. This exciting 3-day program will offer oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into evolving treatment paradigms to optimize care and outcomes for their patients with cancer.
Learning Objectives :
Upon completion of this activity, participants should be better prepared to:
• Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer
• Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
• Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
• Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
• Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer
Additional details will be posted as soon as they are available.
The target audience for this medical event for oncologists, hematologists, nurses, nurse practitioners, and pharmacists interested in the treatment/management of patients with cancer. Radiotherapists, immunologists, fellows, physician assistants, researchers, case managers, and other healthcare professionals interested in the treatment of cancer are also invited to attend. This CME Conference has been approved FOR a maximum of 21.75 AMA PRA Category 1 Credits.
Course Description :
Advances in all aspects of cancer care—including diagnostic, therapeutic, and supportive strategies—form the foundation for recent changes in the management of solid and hematologic malignancies. For many tumor types, integration into practice of novel testing approaches, systemic therapies, molecular targeted therapies, immunotherapies, and multimodal strategies, continue to improve patient outcomes in multiple lines of care. Each year, the CFS®, brings together more than 2,000 oncologists, hematologists, radiation oncologists, immunologists, pharmacists, oncology nurses, nurse practitioners, physician assistants, and case managers, with the aim of promoting the delivery of state-of-the-art cancer care for the most challenging clinical scenarios. At the 34th Annual CFS®, our internationally renowned faculty will provide expert insights on the latest developments in cancer therapeutics. This exciting 3-day program will offer oncology practitioners an unparalleled opportunity to learn how innovative approaches fit into evolving treatment paradigms to optimize care and outcomes for their patients with cancer.
Learning Objectives :
Upon completion of this activity, participants should be better prepared to:
• Determine the most appropriate testing strategies to stratify risk and inform clinical decision-making in the management of cancer
• Describe important clinical trial results that inform treatment practices and are altering care paradigms for patients with hematologic malignancies and solid tumors
• Identify immunotherapeutic, chemotherapeutic, and targeted approaches demonstrated by recent evidence to optimize clinical outcomes
• Delineate methods multidisciplinary teams can proactively apply to prevent and mitigate the impact of treatment-related toxicities findings in the context of evolving treatment pathways to improve care for patients with cancer
• Assess practice-changing evidence and apply these findings in the context of evolving treatment paradigms to optimize the care of patients with cancer
Additional details will be posted as soon as they are available.
KEY DATES
08 Nov, 2017
Event Start Date
10 Nov, 2017
Event End Date
SPECIALITIES
OncologySUGGESTED HOTELS
CONFERENCE VENUE
New York Marriott MarquisRELATED CONFERENCES & LIVE WEBINARS
Quick Links